Skip to main content

CORRECTION article

Front. Immunol., 18 December 2023
Sec. Immunological Tolerance and Regulation
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1352525

Corrigendum: A TNFR2-specific TNF fusion protein with improved in vivo activity

Juan Gamboa Vargas1,2† Jennifer Wagner3† Haroon Shaikh1,2 Isabell Lang3 Juliane Medler3 Mohamed Anany3,4 Tim Steinfatt1 Josefina Peña Mosca1,2 Stephanie Haack1 Julia Dahlhoff1 Maike Büttner-Herold5 Carolin Graf1 Estibaliz Arellano Viera1 Hermann Einsele1 Harald Wajant3*‡ Andreas Beilhack1,2‡
  • 1Interdisciplinary Center for Clinical Research Laboratory, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
  • 2Graduate School of Life Sciences, Würzburg University, Würzburg, Germany
  • 3Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
  • 4Department of Microbial Biotechnology, Institute of Biotechnology, National Research Center, Giza, Egypt
  • 5Department of Nephropathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

A Corrigendum on
A TNFR2-specific TNF fusion protein with improved in vivo activity

by Vargas JG, Wagner J, Shaikh H, Lang I, Medler J, Anany M, Steinfatt T, Mosca JP, Haack S, Dahlhoff J, Büttner-Herold M, Graf C, Viera EA, Einsele H, Wajant H and Beilhack A (2022) Front. Immunol. 13:888274. doi: 10.3389/fimmu.2022.888274

Incorrect Affiliation

In the published article, there was an error in affiliation “4”. Instead of “Department of Microbial Biotechnology, Institute of Biotechnology, Giza, Egypt”, it should be “Department of Microbial Biotechnology, Institute of Biotechnology, National Research Center, Giza, Egypt”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: agonist, GvHD, regulatory T cells, serum retention, TNF, TNFR2

Citation: Gamboa Vargas J, Wagner J, Shaikh H, Lang I, Medler J, Anany M, Steinfatt T, Peña Mosca J, Haack S, Dahlhoff J, Büttner-Herold M, Graf C, Viera EA, Einsele H, Wajant H and Beilhack A (2023) Corrigendum: A TNFR2-specific TNF fusion protein with improved in vivo activity. Front. Immunol. 14:1352525. doi: 10.3389/fimmu.2023.1352525

Received: 08 December 2023; Accepted: 12 December 2023;
Published: 18 December 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Gamboa Vargas, Wagner, Shaikh, Lang, Medler, Anany, Steinfatt, Peña Mosca, Haack, Dahlhoff, Büttner-Herold, Graf, Viera, Einsele, Wajant and Beilhack. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Harald Wajant, harald.wajant@mail.uni-wuerzburg.de

†These authors have contributed equally to this work

‡These authors have contributed equally to this work

Download